Literature DB >> 2200498

Immunohistochemical identification of CA125 and the F(ab')2 fragments of the murine monoclonal antibody OC125 in ovarian cancer tissue.

G Ronay1, W Jäger, K Weiss, H Feistel, F Wolf, A H Tulusan, N Lang.   

Abstract

Benign and malignant tissue samples of 19 ovarian cancer patients who received an intravenous infusion of radiolabelled F(ab')2 fragments of OC125 were examined for expression of CA125 and the cellular location of the injected antibodies. CA125 could be detected by immunohistochemistry in 47 of 71 biopsies containing cancer cells, but not in 258 biopsies with benign tissue. F(ab')2 fragments were found in 34 of these 47 biopsies. The diffuse intracytoplasmic staining pattern seemed to indicate that the injected antibodies had crossed the membranes of the cancer cells. Since the antibody could not be detected in benign tissues, further applications of OC125 for diagnostic and therapeutic purposes seems to be justified.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2200498      PMCID: PMC2149500     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  9 in total

1.  [Radioimmunoscintigraphy in ovarian cancer: theoretical principles and clinical experiences].

Authors:  E Gitsch; N Pateisky
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. II. Biodistribution studies in mice with human tumour xenografts.

Authors:  M V Pimm; A C Perkins; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1985

4.  Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen.

Authors:  D M Goldenberg; E E Kim; F H DeLand; S Bennett; F J Primus
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

5.  Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours.

Authors:  A A Epenetos; K E Britton; S Mather; J Shepherd; M Granowska; J Taylor-Papadimitriou; C C Nimmon; H Durbin; L R Hawkins; J S Malpas; W F Bodmer
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

6.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.

Authors:  D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

7.  Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors.

Authors:  H J Haisma; K R Moseley; A Battaile; T C Griffiths; R C Knapp
Journal:  Am J Obstet Gynecol       Date:  1988-10       Impact factor: 8.661

8.  Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.

Authors:  S E Kabawat; R C Bast; A K Bhan; W R Welch; R C Knapp; R B Colvin
Journal:  Int J Gynecol Pathol       Date:  1983       Impact factor: 2.762

9.  Reactivity of a monoclonal antibody with human ovarian carcinoma.

Authors:  R C Bast; M Feeney; H Lazarus; L M Nadler; R B Colvin; R C Knapp
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.